Table 1 Summary of included studies (references are reported in the Supplementary Material).
From: Comparing CABG and PCI across the globe based on current regional registry evidence
Author | Year | Country/region | No of patients | Mean follow-up (y) | Population comparability | Endpoint long-term mortality |
|---|---|---|---|---|---|---|
Hueb (MASS-II) | 2010 | Brazil | 611 | 10 | RCT | No difference |
Zalweska-Adamiec | 2013 | Poland | 257 | 1.3 | Not adjusted | No difference |
Chou | 2014 | Taiwan | 1287 | 5.4 | MR | Favors CABG |
Sugumar | 2014 | Australia | 8970 | 3.1 | PSM | Favors CABG |
Bangalore | 2015 | New York State, United States | 34,819 | 2.9 | PSM | No difference |
Krishnaswami | 2015 | San Francisco Bay Area, United States | 1015 | 5 | MR | No difference |
Nicolini | 2015 | Italy | 1388 | 5.5 (CABG) 4.4 (PCI) | PSM | Favors CABG |
Lautamäki | 2016 | Finland | 268 | 2.1 | PSM | Favors CABG |
Mølstad | 2016 | Norway | 22,880 | 8 | MR | No difference |
Yamaji | 2016 | Japan | 5651 | 10.1 (CABG) 9.9 (PCI) | MR | Favors CABG |
Zheng | 2016 | China | 4046 | 3 | PSM | Favors CABG |
Nyström | 2017 | Sweden | 2546 | 8 | PSM | Favors CABG |
Roberts | 2017 | North Carolina, United States | 4687 | 5.1 | PSM | Favors CABG |
Iribarne | 2018 | New England, United States | 73,730 | 4.3 | PSM | Favors CABG |
Merkle | 2018 | Germany | 561 | 6 | MR | Favors CABG |
Milojevic | 2018 | Netherlands | 1897 | 39 (CABG) 33 (PCI) | Not adjusted | Favors CABG |
Nagendran | 2018 | Alberta, Canada | 2837 | 5.5 | PSM | Favors CABG |
Ram | 2018 | Israel | 1063 | 3 | MR | Favors CABG |
Shah | 2018 | Great Britain | 717 | 5 | PSM | Favors CABG |
Khosravi | 2019 | Iran | 173 | 0.5 | Not adjusted | No difference |
Lee | 2020 | South Korea | 2240 | 10 | PSM | Favors CABG |
Tam | 2020 | Ontario, Canada | 14,235 | 5.5 | PSM | Favors CABG |
Huckaby | 2021 | Pennsylvania, United States | 1091 | 4 (CABG) 3.5 (PCI) | PSM | Favors CABG |
